This study aims to analyze the effects of long-acting granulocyte colony stimulating factor
(G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are
randomized into study group and control group. In study group, patients accept long-acting
G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather
than long-acting G-CSF. The primary end is the incidence of FN in every course of
chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF
and its expenses, visits to outpatient and emergency clinics, adverse events related to
G-CSF.